Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .

September 22, 2026 updated by: JHM BioPharma (Tonghua) Co. , Ltd.

A Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) in Adult Patients With Upper Limb Spasticity

This is a phase III clinical study to evaluate the efficacy and safety of recombinant botulinum toxin type A（Eveotox）in adult patients with upper limb spasticity. The purpose of this study was to observe efficacy and safety of Eveotox compared with placebo in adult patients with upper limb spasticity.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
207

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • China
    • Anhui
      • Bengbu, Anhui, China
        • Recruiting
        • The First Affiliated Hospital of Bengbu Medical College
        • Contact:
          • Lei Xu
      • Hefei, Anhui, China
        • Recruiting
        • The Second People's Hospital of Hefei
        • Contact:
          • Juncang Wu
    • Beijing Municipality
      • Beijing, Beijing Municipality, China
        • Not yet recruiting
        • Beijing Tsinghua Changgung Hospital
        • Contact:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China
        • Recruiting
        • Three Gorges Hospital affiliated to Chongqing University
        • Contact:
          • Shengli Chen
    • Guangdong
      • Guangzhou, Guangdong, China
        • Recruiting
        • Guangzhou Red Cross Hospital
        • Contact:
          • Zhiwei Mu
    • Guangxi
      • Nanning, Guangxi, China
        • Recruiting
        • Jiangbin Hospital of Guangxi Zhuang Autonomous Region
        • Contact:
          • Xibao Luo
    • Hebei
      • Cangzhou, Hebei, China
        • Recruiting
        • Cangzhou Central Hospital
        • Contact:
          • Yujuan Jiang
      • Shijiazhuang, Hebei, China
        • Recruiting
        • The Second Hospital of Hebei Medical Hospital
        • Contact:
    • Heilongjiang
      • Daqing, Heilongjiang, China
        • Recruiting
        • Oilfields General Hospital in Daqing
        • Contact:
          • Jianghua Liu
      • Harbin, Heilongjiang, China
        • Recruiting
        • The Second Hospital of Harbin
        • Contact:
          • Hongying Li
    • Henan
      • Kaifeng, Henan, China
        • Recruiting
        • The First Affiliated Hospital of Henan University
        • Contact:
          • Qingyan Qin
      • Luoyang, Henan, China
      • Zhengzhou, Henan, China
        • Recruiting
        • The Second Affiliated Hospital of Zhengzhou University
        • Contact:
      • Zhengzhou, Henan, China
        • Recruiting
        • Zhengzhou People's Hospital
        • Contact:
          • Long Tian
    • Hubei
      • Wuhan, Hubei, China
        • Recruiting
        • The Central Hospital of Wuhan
        • Contact:
          • Chaoyang Ma
      • Xiangyang, Hubei, China
        • Recruiting
        • Xiangyang First People's Hospital
        • Contact:
          • Xudong Ding
    • Hunan
      • Changsha, Hunan, China
        • Recruiting
        • The Second Xiangya Hospital of Central South University
        • Contact:
    • Jiangsu
      • Huai'an, Jiangsu, China
        • Active, not recruiting
        • Huai 'an Second People's Hospital
      • Suzhou, Jiangsu, China
        • Recruiting
        • The Second Affiliated Hospital of Soochow University
        • Contact:
      • Xuzhou, Jiangsu, China
        • Recruiting
        • Affiliated Hospital of Xuzhou Medical University
        • Contact:
          • Jie Xiang
    • Jiangxi
      • Pingxiang, Jiangxi, China
        • Recruiting
        • Pingxiang People's Hospital
        • Contact:
    • Liaoning
      • Shenyang, Liaoning, China
        • Recruiting
        • Shengjing Hospital affiliated to China Medical University
        • Contact:
    • Neimenggu
      • Baotou, Neimenggu, China
        • Recruiting
        • Baotou Steel Hospital in Inner Mongolia
        • Contact:
          • Hongzhe Bi
    • Shandong
      • Yantai, Shandong, China
      • Zibo, Shandong, China
        • Recruiting
        • Zibo municipal hospital
        • Contact:
          • Zengqiang Sun
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Recruiting
        • Yangzhi Affiliated Rehabilitation Hospital of Tongji University
        • Contact:
      • Shanghai, Shanghai Municipality, China
    • Shanxi
      • Taiyuan, Shanxi, China
        • Recruiting
        • Shanxi Bethune Hospital
        • Contact:
          • Pingzhi Wang
      • Xianyang, Shanxi, China
        • Recruiting
        • Xianyang Hospital of Yan 'an University
        • Contact:
          • Aihong Guo
    • Sichuan
      • Meishan, Sichuan, China
        • Recruiting
        • Meishan Cardiovascular and Cerebrovascular Hospital
        • Contact:
          • Rong Zhang
      • Shiyan, Sichuan, China
        • Recruiting
        • Taihe hospital of Shiyan City
        • Contact:
          • Xiaohu Zhu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participant must be 18 to 80 years of age inclusive, at the time of signing the informed consent
  • Participants with stable post-stroke Spasticity (ULS) for at least 3 months
  • Participants with Modified Ashworth Scale (MAS) score of at least 2 at elbow flexor or wrist flexor or finger flexor
  • Participants with DAS score of at least 2 on the Principal Target of Treatment (PTT) (one of four functional domains: dressing, hygiene, limb position and pain)
  • Participants who have been stable for at least 1 month prior to study entry in terms of oral antispasticity

Exclusion Criteria:

  • Previous use of any botulinum toxin within 6 months prior to screening, or plan to use any botulinum toxin during the study.
  • History of alcohol or drug abuse.
  • Known allergy or hypersensitivity to any component of the study products.
  • History of epilepsy
  • Known or suspected to be HIV positive, serologically positive for syphilis, or active hepatitis B or C
  • Any medical condition that may put the participant at increased risk for botulinum toxin type A use

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Treatment Group

Eveotox will be administered in double-blind fashion at cycle 1 followed by up to 3 open-label cycles of Eveotox.
Drug: Recombinant Botulinum Toxin Type A for injection

Recombinant Botulinum Toxin Type A for injection
Placebo Comparator: Placebo-Controlled Group

Placebo will be administered in double-blind fashion during treatment cycle 1 only, followed by up to 3 cycles of Eveotox.
Drug: Placebo

Placebo will be administered in double-blind fashion during treatment cycle 1 only

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Primary Outcome Measure
Time Frame: Within 4 weeks

Change from baseline at week 4 for primary targeted muscle group on the MAS(Modified Ashworth Scale).
Within 4 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Secondary Outcome Measure
Time Frame: Within 52 weeks

Incidence of adverse events and drug-related adverse events during the study.
Within 52 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
JHM BioPharma (Tonghua) Co. , Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 11, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 1, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 17, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 17, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 21, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 23, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 22, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • JHM03-CT302

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings